Study wrapper · #728
Mitochondrial-derived peptides MOTS-c and humanin attenuate dexamethasone-induced atrophy in human skeletal muscle cells.
Editor's note
Using human skeletal-muscle cells (myotubes), researchers tested whether MOTS-c and a humanin analogue (HNG) counter dexamethasone-induced muscle wasting. MOTS-c co-treatment fully preserved myotube size and the fusion index, increased Akt signalling, and blunted the atrophy driver MURF1 and STAT3 activation; HNG preserved size but had narrower effects. Notably these are human-derived cells, which strengthens translational relevance over rodent work, but it remains in vitro: no living organism, no dosing, no systemic context. These are preclinical findings; human clinical data are needed before conclusions can be drawn. The signal, MOTS-c limiting glucocorticoid-driven atrophy pathways, is mechanistically coherent and consistent with MOTS-c's exercise-mimetic reputation, but stands on a single cell-culture experiment.
Plain-language abstract
Steroid medicines like dexamethasone are widely used but can waste away muscle. Researchers tested whether two mitochondria-derived peptides, MOTS-c and a humanin version (HNG), could protect human muscle cells grown in the lab. They exposed fully developed human muscle-cell fibres to dexamethasone, with or without the peptides. The steroid shrank the fibres and switched on muscle-breakdown genes. MOTS-c completely preserved fibre size and maturity, boosted a growth-signalling protein (Akt), and reduced two drivers of muscle loss (MURF1 and STAT3). HNG preserved size too but had fewer effects. Because these were human cells, the results may translate better than animal studies, but this was still a lab-dish experiment with no living people involved, so it cannot show real-world benefit; human trials would be needed. The findings suggest MOTS-c may act against steroid-driven muscle wasting, in line with its reputation as an "exercise-mimicking" molecule.